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Abstract 
The objective of our study was to determine the utility of a baseline high sensitivity cardiac 
troponin (hs-cTnI) value below the limit of quantitation to rule out acute myocardial infarction 
(AMI) in patients presenting to the emergency department with any suspicious symptoms of a 
cardiac etiology. We enrolled subjects presenting to the Emergency Department with symptoms 
suspicious for AMI. Blood specimens were collected within one hour after a triage 
electrocardiogram. Cardiac troponin I was measured using the Beckman Coulter Access hs-cTnI 
assay. The diagnosis of AMI was adjudicated by two cardiologists using the Third Universal 
Definition of AMI and Roche Diagnostics Troponin T Generation 5 assay with all available 
clinical data at 30 days after presentation. A total of 567 subjects had all data required for data 
analyses. AMI was diagnosed in 46 (8.1%) patients. 232 (40.9%) individuals had presentation 
hs-cTnI results < 4.0 ng/L. None of the patients with baseline hs-cTnI < 4.0 ng/L had an AMI, 
yielding a negative predictive value of 100.0% and a sensitivity of 100%, and a good prognosis 
(no AMIs or cardiac-related deaths at 30 days). In this single center emergency department 
study, a baseline presenting novel hs-cTnI value of < 4.0 ng/L effectively ruled out AMI in 
40.9% of all patients presenting to the emergency department and having any symptoms 
suspicious for AMI. Importantly all patients, not only those with chest pain, and those having 
symptoms for any duration or those with end-stage renal disease requiring dialysis were 
included.  
Keywords: 
High sensitivity troponin, myocardial infarction, emergency rule-out 
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Introduction 
In the United States (US), the incidence of acute myocardial infarction (AMI) has been estimated 
at 1,055,000 individuals per year.1  Chest pain and other related symptoms are very common 
presentations to the emergency department (ED) with approximately 7 million patients in the 
United States evaluated annually.2  
Due to delays in AMI exclusion, most patients presenting to the ED with symptoms suspicious 
for AMI are admitted or have an extended stay in an observation unit (up to 88% in some 
centers).3 However, only a minority of these patients are diagnosed with AMI. In the US, the 
annual estimated cost of evaluating patients with possible AMI in the ED is approximately $5 
billion.4 In addition, the delay in exclusion of AMI can lead to ED overcrowding and contribute 
to increased associated health care costs.5 Hence, there is a need for a rapid and accurate tool for 
AMI diagnosis.  
Clinical history and electrocardiography (ECG) alone are not enough to achieve early and 
efficient AMI diagnosis without additional testing with cardiac troponin (cTn) assays.6 High 
sensitivity cardiac troponin (hs-cTn) assays can quantify low cTn concentrations with great 
precision  and can help in early detection of AMI .7 A meta-analysis of studies using the  hs-
cTnT assay (Roche Diagnostics, Indianapolis, IN) demonstrated that cut-offs of 3-5 ng/L (6 
studies) had a sensitivity of 97.4% and specificity was 42.4%.8 The overall negative predictive 
value (NPV) of the hs-cTnT assay (< 5 ng/L cut-off), used alone or accompanied with no-
ischemic-ECG changes, was > 99%.9,10 cTn results below these very low levels could help 
discharge patients safely and early from the ED and allow resources to be focused on 
intermediate and high risk cases.  
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The American Heart Association/American College of Cardiology guidelines from 2014 for 
management of patients with non-ST-elevation AMI still recommend the measurement of cTn 
over 3 to 6 hours with levels above the 99th percentile upper reference limit for determination of 
AMI.11 However, these recommendations were made prior to the introduction of hs-cTn assays 
that are now widely available in the United States. On the other hand, the European Society of 
Cardiology guidelines recommend a rule-out strategy that can be applied by using a focus on the 
1 value at presentation and at 1 hour, or very low levels below level of detection at 
presentation.12 There is evidence suggesting that triage decisions using hs-cTn results at 
presentation could potentially decrease cost and time compared to serial testing in certain 
patients.13 
The analytical performance of the new Beckman Coulter Access hs-cTnI (Brea, CA) has been 
examined with excellent results reported.14 Most of the clinical reports found in the literature 
have utilized hs-cTnT (Roche Diagnostics)15,16 and hsTnI (Abbott Diagnostics, Abbott Park, 
IL)17,18 assays and validated the utility of these assays in ruling out AMI. However, less evidence 
is published on the clinical performance of the new Beckman Coulter Access hs-cTnI and these 
are primarily from outside the United States.19-21 The objective of our study was to determine the 
optimal cutoff(s) for ruling out AMI at presentation using the Beckman Coulter Access hs-cTnI 
assay in the United States population, and to confirm baseline low hs-cTnI threshold using a 
validated hs-cTnT criteria.  
Methods 
A prospective, observational trial enrolled subjects presenting to the ED at Henry Ford Hospital 
(Detroit, Michigan) who were evaluated for possible AMI. Inclusion criteria were subjects 21 
years or older presenting with clinical symptoms suspicious for AMI that led the responsible 
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clinician to order an ECG and cTn, and were able to consent and comply with the protocol. 
Exclusion criteria were patients needing immediate life-saving interventions, 
cardioversion/defibrillation or thrombolytic therapy in the previous 24 hours, ST-segment 
myocardial infarction requiring immediate reperfusion therapy, traumatic injuries, transfers from 
other facilities, and pregnant or breast-feeding females. The study was approved by the Henry 
Ford Hospital Institutional Review Board and subjects provided written informed consent before 
being enrolled. The study was conducted according to the Declaration of Helsinki and 
International Conference of Harmonization good clinical practice guidelines. Study subjects 
were assessed by an emergency physician, which included patient history, physical examination, 
a review of ECG, customary blood testing that included cTnI, and chest X-ray. The treating 
emergency physician determined the timing and implementation of these tests, treatments, and 
dispositions. After obtaining informed consent, research study coordinators obtained a detailed 
symptoms history, which was recorded on the study case report form. Subjects were directly 
asked about their medical history and this was verified by review of their electronic medical 
record. 
Blood Testing 
Blood specimens were collected in plain (no additive) serum tubes and dipotassium 
ethylenediaminetetraacetate evacuated plasma tubes within 1 hour after the triage ECG was 
completed (usually within 10 minutes of presenting). An additional blood specimen was obtained 
at 3 hours after presentation (SD 15 minutes or +/- 15 minutes). Specimens were centrifuged to 
obtain serum or plasma and stored at -80°C within 1 hour of collection. Frozen plasma 
specimens (-80°C) were thawed once and hs-cTnI was measured using the Access 2 
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immunoassay system (Beckman Coulter, Inc.) in the clinical laboratory at Henry Ford Hospital. 
Samples from the presentation and 3 hours collections were measured.  
The Beckman Coulter published limit of detection (equivalent to the limit of quantitation [LoQ] 
at a 20% coefficient of variation) and LoQ at 10% coefficient of variation are 2.0 and 4.0 ng/L, 
respectively. The hs-cTnI assay is reported by Beckman Coulter to have an overall 99th 
percentile upper reference limit of healthy subjects of 18.2 ng/L, with sex-specific upper 
reference limits of 11.8 ng/L (females) and 19.7 ng/L (males). 
Clinical Outcomes 
The final diagnosis of type 1 AMI or type 2 AMI was adjudicated by a cardiologist and an 
emergency physician with additional review by a second cardiologist in cases of disagreement.  
The diagnosis of AMI was based on the Third Universal Definition of Myocardial Infarction and 
Elecsys Troponin T Generation 5 assay using a Roche Cobas e601 analyzer (Roche Diagnostics) 
with all available clinical data 30 days after presentation and required at least 1 hs-cTnT result > 
19 ng/L. 
The adjudicators were not aware of the research study biomarker data. A telephone call and a 
subsequent medical record review was used to obtain follow-up information. When subjects or 
family members were not able to be contacted, a death registry search was completed. The Social 
Security Death Index was searched if the subject’s social security number was known, and 
unknown cases were searched using Ancestry.com, Michigan obituaries, and a Google search. 
An Access hs-cTnI assay LoQ cut-off of 4.0 ng/L was used to categorize to either a rule-in or 
rule-out group. Additionally, for subjects not assigned to the ruled-out group, we calculated the 
positive predictive value and specificity for diagnosing AMI. As appropriate, 95% confidence 
limits were calculated around all statistics. The patients with a baseline hs-cTnI result less than 
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4.0 versus 4.0 or greater were compared using 2-sample t-tests for the continuous data, chi-
square tests for the non-sparse categorical data, and Fisher exact tests for sparse categorical data. 
P-values less than 0.05 were considered statistically significant. All analysis was performed 
using SAS versions 9.4 (SAS Institute, Inc., Cary, NC). 
Results 
During the period of May 2013 through April 2015, there were 575 subjects enrolled, of which 
567 had acceptable data for inclusion in the analysis (Figure 1). The adjudicated final diagnosis 
demonstrated AMI present in 46 AMI patients (8.1%). Twenty-eight of the AMIs were type 1 
and 18 were type 2. 
Patients were divided into those with hs-cTnI values < 4.0 ng/L (rule-out) and > 4.0 ng/L (not 
rule-out) along with clinical features, comorbidities, vital signs, ECG findings, and medications 
(Table 1). Those subjects with intermittent symptoms had time of symptom onset and the longest 
duration of these symptoms documented.  
Two hundred thirty-two (40.9%) patients had values < 4.0 ng/L (Table 2). Further, a presentation 
hs-cTnI value of < 4.0 ng/L yielded an NPV of 100.0% (95% CI 98.4%-100.0%), and a 
sensitivity of 100.0% (95% CI 92.3%-100.0%). Among the patients who had a baseline value < 
4.0 ng/L, only 1 patient died of non-cardiac etiology within 30-days and no AMI occurred. 
Within the set of 232 subjects who had a baseline hs-cTnI result of < 4.0 ng/L, the emergency 
discharge disposition consisted of 91 (39%) to home, 94 (41%) to observation, 38 (16%) were 
admitted, 8 (3%) left against medical advice, and 1 (0.4%) transferred to another facility. 
Electronic medical records of all study subjects were reviewed. One hundred nine of the subjects 
could not be contacted for the 30-day telephone interview. Of the subjects who could not be 
contacted by phone, no AMIs or cardiac-related deaths occurred. On further analysis of the 30- 
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to 45-day follow-up period, there were 8 AMIs and 7 deaths (4 with a cardiac-caused death). 
Two of the patients had an AMI resulting in death, resulting in a total of 13 AMI/death outcomes 
after 30-45 days of follow-up. During the 12- to 18-month follow-up period, there were 19 AMIs 
and 21 deaths (9 from cardiac causes). Five of the patients had an AMI resulting in death, 
resulting in a total of 35 AMI/death outcomes after 12 to 18 months of follow-up. 
Discussion 
In this single center prospective ED study, a baseline Beckman Coulter hs-cTnI assay value of < 
4.0 ng/L at presentation could have effectively ruled out AMI in 40.9% of all patients presenting 
to the ED with AMI symptoms. The 100% diagnostic sensitivity result demonstrates the safety of 
these baseline thresholds to rule out AMI at presentation and 30 days. Noteworthy, all patients 
with symptoms suspicious for AMI regardless of symptoms duration, recent AMI diagnosis in 
the last 3 weeks, or renal function status (chronic kidney disease or dialysis) were included in the 
study. Our cohort could represent a practical assessment of performance of the hs-cTnI assay for 
patients presenting to ED with symptoms suspicious for AMI. 
To our knowledge, this is the first report of the utility of a baseline hs-cTnI assay by using the 
Beckman Coulter hs-cTnI assay to rule in or rule out AMI in a US ED. Other groups have 
reported effective triaging of chest pain patients using hs-cTn assays (both cTnT and cTnI). 
Recently, Boeddinghaus et al reported excellent diagnostic accuracy of the Beckman Coulter hs-
cTnI assay in a large European multi-center validation.22 Because the Beckman Coulter hs-cTnI 
assay is now available in the US as an aid in the diagnosis of myocardial infarction, it is vital to 
determine how best to capitalize on the added sensitivity of this assay in a US population. Our 
results obtained using the Beckman Coulter hs-cTnI assay at a cut-off of the LoQ (10% 
coefficient of variation) ruled out AMI with high confidence. Similar to our study, Boeddinghaus 
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et al demonstrated essentially equivalent performance with a NPV of 99.8% and a sensitivity of 
98.9% in their validation cohort. We were able to rule out AMI in 40.9% of subjects, which 
compares favorably with the 43% rule out that Boeddinghaus reported. 
Different hs-cTn assays offer very high NPV and very good identification of low risk patients 
who present with symptoms suspicious for AMI. The concentration threshold has been fairly 
similar in variable assays in different studies. Abbott hs-cTnI assay, Roche Diagnostics hs-cTnT, 
Abbott Atellica IM hs-cTnI assay and Siemens ADVIA Centaur hs-cTnI (Malvern, PA) have 
used a threshold of < 5 ng/L, which could help simplify the diagnostic approach in different 
institutions.10,23-26 Our study demonstrated that a cut off of < 4.0 ng/L can effectively rule-out 
AMI in symptomatic patients presenting to the ED, which is very close to thresholds reported in 
other studies, and produced excellent results with 5 ng/L although slightly poorer but 1 AMI was 
missed. In fact, all 46 AMI patients had a baseline hs-cTnI reading of 4.0 ng/L or greater while 
45 had a baseline hs-cTnI reading of 5.0 ng/L or greater. It is recognized that troponin assays are 
not standardized between manufacturers and comparison of cut-offs has certain limitations.  For 
the potential clinical application of this cut-off, a practical consideration would be to use whole 
numbers for reporting patient values to physicians. 
Recently published data from the HIGH-US multi-center study demonstrated the applicability of 
U.S. Food and Drug Administration-cleared hs-cTnI assays in the US for risk stratification and 
ruling out AMI using the Siemens assay.23 The hs-cTnI threshold of < 5 ng/L was used and 
allowed identification of 46%-47% of subjects at lower risk with an NPV of 99.6% for AMI or 
death at 30 days. Our study demonstrated comparable outcomes, with 41% being ruled out of 
AMI and a similarly excellent NPV using the Beckman Coulter hs-cTnI assay. 
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Although it has not been implemented in the American Heart Association/American College of 
Cardiology guidelines yet, the use hs-cTnI has been acknowledged in the European guidelines 
for many years and it is a Class I recommendation.11 The use of single baseline hs-cTnI could 
help with early discharge of patients and provide economic value by decreasing length of stay 
and overall healthcare costs. Our study provides evidence that using a single cardiac marker 
measurement with very high sensitivity and NPV can support decisions in accurate disposition of 
patients presenting with symptoms suspicious for AMI to the ED. This has been demonstrated to 
be true using a different hs-cTnI assay in the US population in a prior study.23 
A single baseline hs-cTnI result below the 10% CV LoQ portends a good prognosis, as only 1 
patient died from non-cardiac causes and no AMIs were documented at 30 days. The modest 
number of events beyond 30 days in the current report, and inability of very low hs-cTnI values 
to recognize those patients at very low risk in future months and years, is not entirely consistent 
with published work from others and deserves further study.27-29  
Further tools for risk stratification, including ECG, HEART score, or further coronary artery 
disease testing may not provide an incremental value at these very low hs-cTnI concentrations. 
Nestelberger et al found that factoring in the likelihood of acute coronary syndrome or ischemic 
ECG changes did not improve prediction of AMI or major adverse cardiac events and actually 
lessened the number of subjects who were ruled out as low risk or those discharged home.30 
Additionally, it has been shown that there is an incremental but still extremely low risk of AMI 
and major adverse cardiac events at hs-cTn threshold values of < 2 ng/L and < 5 ng/L, compared 
to hs-cTn of > 5 ng/L but less than the 99th percentile upper reference limit, allowing more 
patients to be discharged with a slightly higher threshold value.27 Additional studies are needed 
to validate our single baseline value < LoQ for AMI rule out and to determine the appropriate 1- 
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or 3-hour delta values that might provide further guidance for managing ED patients with 
possible AMI. 
Study Limitations 
This study has several limitations that may affect application or generalization of our findings. 
This is a single center urban ED study, which may require further validation of our cut-off of 4.0 
ng/L with different demographics for widespread adoption of this assay threshold. Additionally, 
as this was an opportunistic study, patients presenting were screened for enrollment only when 
research staff were present. Typically, there were 3 shifts a day dedicated to the study on 
Monday through Thursday and 1 or 2 shifts on Fridays. No subject recruitment occurred 
Saturdays or Sundays. The adjudicated diagnosis of AMI in our cohort used the Roche Elecsys 
TnT Generation 5 assay. It is not entirely understood the relationship between the cTnT assay 
used to adjudicate and our hs-cTnI assay given these two assays measure different forms of cTn 
and potentially different aspects of pathophysiologic processes occurring in cardiac ischemia. 
Last, we were unable to conduct the 30-day telephone interview with almost half of the study 
cohort; however, chart reviews were conducted to complete the necessary follow up.  
In conclusion, in this single center ED study, a baseline presenting novel hs-cTnI value < 4.0 
ng/L effectively ruled out AMI in 40.9% of all patients presenting to the ED and having any 
symptoms suspicious for AMI. Importantly, all patients presenting with acute coronary 
syndrome symptoms having symptoms for any duration were enrolled, including patients on 
dialysis and with end-stage renal disease.  
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Figure Legends 
Figure 1. Patients’ enrollment process and the included final qualified patient cohort. 
Abbreviations: ECG, electrocardiogram; TnI, troponin I. 
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Table 1. Baseline clinical characteristics for all patients and for patients with baseline Beckman 
Coulter’s hs-cTnI assay of < 4.0 ng/L (rule-out) vs > 4.0 ng/L (rule-in) groups  
Characteristics 
All Qualified Patients 
(N=567) 
Beckman Baseline hs-cTnI 
P-value <4.0 ng/L (N=232) ≥4.0 ng/L (N=335) 
Age, mean ± SD, median 
(IQR), years 
55.8 ± 11.1, 55 (49-63) 52.7 ± 10.3, 52 (46-59) 58.0 ± 11.2, 58 (51-65) <0.001 
Male gender (%) 296 (52.2) 84 (36.2) 212 (63.3) <0.001 
Comorbidities (%) 
  Hypertension 462 (81.5) 159 (68.5) 303 (90.4) <0.001 
  Diabetes 164 (28.9) 58 (25.0) 106 (31.6) 0.086 
  Hypercholesterolemia 285 (50.3) 91 (39.2) 194 (57.9) <0.001 
  Smoking 211 (37.2) 92 (39.7) 119 (35.5) 0.317 
  Personal history of CAD 204 (36.0) 60 (25.9) 144 (43.0) <0.001 
  Family history of CAD 220 (38.8) 73 (31.5) 147 (43.9) 0.003 
  Revascularization 140 (24.7) 38 (16.4) 102 (30.4) <0.001 
  PCI 129 (22.8) 37 (15.9) 92 (27.5) 0.001 
  CABG 31 (5.5) 6 (2.6) 25 (7.5) 0.012 
  Myocardial infarction 168 (29.6) 46 (19.8) 122 (36.4) <0.001 
  Congestive heart failure  137 (24.2) 27 (11.6) 110 (32.8) <0.001 
  Dialysis 30 (5.3) 0 (0.0) 30 (9.0) <0.001 
  COPD 98 (17.3) 39 (16.8) 59 (17.6) 0.804 
Presenting vital signs, mean ± SD, median (IQR) 
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  Systolic BP, mm Hg 144.8 ± 25.9, 143 (127-
159) 
140.5 ± 22.2, 138.5 
(125-153) 
147.7 ± 27.9, 145 (128-
164) 
<0.001 
  Diastolic BP, mm Hg 85.5 ± 17.5, 83 (74-97) 84.4 ± 15.4, 82 (74.5-
95) 
86.3 ± 18.8, 83 (73-98) 0.175 
  Heart rate, beats/min 83.9 ± 18.9, 82 (70-95) 82.9 ± 17.7, 81 (70.5-
92) 
84.5 ± 19.7, 82 (70-96) 0.337 
ECG findings (%) 
  Atrial fibrillation 
tachycardia 
20 (3.5) 2 (0.9) 18 (5.4) 0.004 
  Sinus tachycardia 74 (13.1) 23 (9.9) 51 (15.2) 0.065 
  Other tachycardia 10 (1.8) 4 (1.7) 6 (1.8) 1.000 
  Left ventricular hypertrophy 94 (16.6) 21 (9.1) 73 (21.8) <0.001 
  Left bundle branch block 10 (1.8) 0 (0.0) 10 (3.0) 0.007 
  Right bundle branch block 27 (4.8) 3 (1.3) 24 (7.2) 0.001 
  V-paced 13 (2.3) 1 (0.4) 12 (3.6) 0.014 
  ST-segment elevation > 1 20 (3.5) 9 (3.9) 11 (3.3) 0.705 
  ST-segment depression > 1 25 (4.4) 3 (1.3) 22 (6.6) 0.003 
  T-wave inversion 169 (29.8) 34 (14.7) 135 (40.3) <0.001 
  ECG tracing within normal 
limits 
153 (27.0) 102 (44.0) 51 (15.2) <0.001 
Home medications (%) 
  Aspirin 300 (52.9) 98 (42.2) 202 (60.3) <0.001 
  Anti-coagulant 49 (8.6) 12 (5.2) 37 (11.0) 0.014 
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  Diuretics 141 (24.9) 46 (19.8) 95 (28.4) 0.021 
  ACE inhibitor 218 (38.4) 64 (27.6) 154 (46.0) <0.001 
  Angiotensin receptor 
blocker 
38 (6.7) 9 (3.9) 29 (8.7) 0.025 
  Beta blocker 256 (45.1) 66 (28.4) 190 (56.7) <0.001 
  Calcium channel blocker 144 (25.4) 41 (17.7) 103 (30.7) <0.001 
  Nitrates 129 (22.8) 37 (15.9) 92 (27.5) 0.001 
  Anti-arrhythmic 14 (2.5) 2 (0.9) 12 (3.6) 0.040 
ACE, angiotensin converting enzyme; BP, blood pressure; CABG, coronary artery bypass graft; 
CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; ECG, 
electrocardiogram; hs-cTnI, high sensitivity cardiac troponin I; PCI, percutaneous coronary 
intervention. 
Categorical data is given as frequency (%) measurements. Numerical data is given as mean 
(standard deviation [SD]) and median (interquartile range [IQR]) values. 
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Table 2. The ability of various cut-points to predict hs-cTnT defined AMI final diagnosis 
hs-cTnI (ng/L) 4.0 5.0 18.0 20.0 (males) 15.0 (females) 
Sensitivity (%) 100.0 
(92.3-100.0) 
97.8 
(88.5-99.9) 
82.6 
(68.6-92.2) 
77.8 
(57.7-91.4) 
89.5 
(66.9-98.7) 
Specificity (%) 44.5 
(40.2-48.9) 
51.8 
(47.4-56.2) 
84.3 
(80.8-87.3) 
81.0 
(75.8-85.6) 
88.9 
(84.3-92.5) 
Negative predictive 
value (%) 
100.0 
(98.4-100.0) 
99.6 
(98.0-100.0) 
98.2 
(96.5-99.2) 
97.3 
(94.3-99.0) 
99.1 
(96.8-99.9) 
Positive predictive 
value (%) 
13.7 
(10.2-17.9) 
15.2 
(11.3-19.8) 
31.7 
(23.5-40.8) 
29.2 
(19.0-41.1) 
37.8 
(23.8-53.5) 
AMI, acute myocardial infarction; hs-cTnI, high sensitivity cardiac troponin I. 
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